Cargando…
Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer
BACKGROUND: Sentinel lymph node biopsy (SLNB) provides staging information and guides adjuvant therapy in early breast cancer (EBC). Routine SLNB in oncogeriatricians with low-risk EBC remains controversial. AIMS: To evaluate axillary management in elderly patients diagnosed with oestrogen receptor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207274/ https://www.ncbi.nlm.nih.gov/pubmed/34177266 http://dx.doi.org/10.1177/11782234211022203 |
_version_ | 1783708741479170048 |
---|---|
author | Davey, Matthew G Ryan, Éanna J Burke, Daniel McKevitt, Kevin McAnena, Peter F Kerin, Michael J Lowery, Aoife J |
author_facet | Davey, Matthew G Ryan, Éanna J Burke, Daniel McKevitt, Kevin McAnena, Peter F Kerin, Michael J Lowery, Aoife J |
author_sort | Davey, Matthew G |
collection | PubMed |
description | BACKGROUND: Sentinel lymph node biopsy (SLNB) provides staging information and guides adjuvant therapy in early breast cancer (EBC). Routine SLNB in oncogeriatricians with low-risk EBC remains controversial. AIMS: To evaluate axillary management in elderly patients diagnosed with oestrogen receptor positive (ER+), clinically lymph node negative (cLN−) EBC, and to assess whether SLNB affects further axillary management or adjuvant chemotherapy (ACTX) decision making. METHODS: Female patients aged > 65 years, diagnosed with ER+, human epidermal growth factor receptor-2 negative (HER2−), and cLN− breast cancer (BC), who underwent surgery and SLNB were included. Clinicopathological predictors of ACTX and completion axillary lymph node dissection (CALND) were determined. Kaplan-Meier analyses assessed survival outcomes. RESULTS: A total of 253 patients were included (median age: 72 years, range: 66-90), all underwent SLNB; 50 (19.8%) had lymphatic metastasis on SLNB (SLNB+). Of these, 19 proceeded to CALND (38.0%), 10 (52.6%) of whom had further axillary disease (ALND+). 20 of the 50 SLNB+ patients received ACTX (40.0%) as did 31 of the 203 SLNB− patients (15.2%) (P < .001). Oncotype DX (ODX) testing was utilized in 82 cases (32.8%). Younger age (P < .001), SLNB+ (P < .001) and ODX score (P = .003) were all associated with ACTX prescription. ODX > 25 (OR: 4.37, 95% CI: 1.38-13.80, P = .012) independently predicted receiving ACTX. Receiving ACTX and proceeding to CALND did not improve disease-free (P = .485 and P = .345) or overall survival (P = .981 and P = .646). CONCLUSIONS: Routine SNLB may not be necessary in elderly patients diagnosed with ER+, cLN− EBC. Future oncogeriatric practice is likely to see genomic testing guiding ACTX prescription in this group. |
format | Online Article Text |
id | pubmed-8207274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82072742021-06-25 Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer Davey, Matthew G Ryan, Éanna J Burke, Daniel McKevitt, Kevin McAnena, Peter F Kerin, Michael J Lowery, Aoife J Breast Cancer (Auckl) Original Research BACKGROUND: Sentinel lymph node biopsy (SLNB) provides staging information and guides adjuvant therapy in early breast cancer (EBC). Routine SLNB in oncogeriatricians with low-risk EBC remains controversial. AIMS: To evaluate axillary management in elderly patients diagnosed with oestrogen receptor positive (ER+), clinically lymph node negative (cLN−) EBC, and to assess whether SLNB affects further axillary management or adjuvant chemotherapy (ACTX) decision making. METHODS: Female patients aged > 65 years, diagnosed with ER+, human epidermal growth factor receptor-2 negative (HER2−), and cLN− breast cancer (BC), who underwent surgery and SLNB were included. Clinicopathological predictors of ACTX and completion axillary lymph node dissection (CALND) were determined. Kaplan-Meier analyses assessed survival outcomes. RESULTS: A total of 253 patients were included (median age: 72 years, range: 66-90), all underwent SLNB; 50 (19.8%) had lymphatic metastasis on SLNB (SLNB+). Of these, 19 proceeded to CALND (38.0%), 10 (52.6%) of whom had further axillary disease (ALND+). 20 of the 50 SLNB+ patients received ACTX (40.0%) as did 31 of the 203 SLNB− patients (15.2%) (P < .001). Oncotype DX (ODX) testing was utilized in 82 cases (32.8%). Younger age (P < .001), SLNB+ (P < .001) and ODX score (P = .003) were all associated with ACTX prescription. ODX > 25 (OR: 4.37, 95% CI: 1.38-13.80, P = .012) independently predicted receiving ACTX. Receiving ACTX and proceeding to CALND did not improve disease-free (P = .485 and P = .345) or overall survival (P = .981 and P = .646). CONCLUSIONS: Routine SNLB may not be necessary in elderly patients diagnosed with ER+, cLN− EBC. Future oncogeriatric practice is likely to see genomic testing guiding ACTX prescription in this group. SAGE Publications 2021-06-14 /pmc/articles/PMC8207274/ /pubmed/34177266 http://dx.doi.org/10.1177/11782234211022203 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Davey, Matthew G Ryan, Éanna J Burke, Daniel McKevitt, Kevin McAnena, Peter F Kerin, Michael J Lowery, Aoife J Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer |
title | Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer |
title_full | Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer |
title_fullStr | Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer |
title_full_unstemmed | Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer |
title_short | Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer |
title_sort | evaluating the clinical utility of routine sentinel lymph node biopsy and the value of adjuvant chemotherapy in elderly patients diagnosed with oestrogen receptor positive, clinically node negative breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207274/ https://www.ncbi.nlm.nih.gov/pubmed/34177266 http://dx.doi.org/10.1177/11782234211022203 |
work_keys_str_mv | AT daveymatthewg evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer AT ryaneannaj evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer AT burkedaniel evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer AT mckevittkevin evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer AT mcanenapeterf evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer AT kerinmichaelj evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer AT loweryaoifej evaluatingtheclinicalutilityofroutinesentinellymphnodebiopsyandthevalueofadjuvantchemotherapyinelderlypatientsdiagnosedwithoestrogenreceptorpositiveclinicallynodenegativebreastcancer |